What CGT can learn from biologics: high‑value AI use cases for manufacturing
Year: 2026
Type: article
Abstract: Cell and gene therapy manufacturing continues to face efficiency and scalability challenges, yet the sector can draw directly on the biopharmaceutical industry’s established experience applying AI and machine learning across biologics production, spanning digital infrastructure, process analytical technology (PAT), cloud-based digital applications, and generative AI. This article examines how those lessons translate to CGT, arguing that manufacturers should prioritize electronic batch records, contextualized metadata, and cloud-based data pipelines before layering on advanced AI, while planning early for GMP validation of AI-driven tools.
Source: Cell and Gene Therapy Insights
Author: Shyam Panjwani
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: hybrid
OpenAlex ID: W7172024938
FWCI:
Cites:
Cited by:
Related to: